Arch Therapeutics Stock Today

ARTH Stock  USD 1.96  0.14  7.69%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 42

 
100  
 
Zero
Below Average
Arch Therapeutics is trading at 1.96 as of the 29th of March 2024. This is a 7.69 percent up since the beginning of the trading day. The stock's open price was 1.82. Arch Therapeutics has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Arch Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of May 2022 and ending today, the 29th of March 2024. Click here to learn more.
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 249.94 M outstanding shares. More on Arch Therapeutics

Moving together with Arch OTC Stock

  0.88BA Boeing Fiscal Quarter End 31st of March 2024 PairCorr

Moving against Arch OTC Stock

  0.95TRV The Travelers Companies Fiscal Quarter End 31st of March 2024 PairCorr
  0.92IBM International Business Fiscal Quarter End 31st of March 2024 PairCorr
  0.9AXP American Express Sell-off TrendPairCorr
  0.9WMT Walmart Financial Report 16th of May 2024 PairCorr
  0.89MSFT Microsoft Fiscal Quarter End 31st of March 2024 PairCorr
  0.87MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.86DIS Walt Disney Aggressive PushPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Arch OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Arch Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arch Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEO, DirectorTerrence Norchi
Business ConcentrationHealth Care, Health Care Equipment & Supplies, Biotechnology, Healthcare (View all Sectors)
Arch Therapeutics [ARTH] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arch Therapeutics's market, we take the total number of its shares issued and multiply it by Arch Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Arch Therapeutics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 249.94 M outstanding shares. Arch Therapeutics currently holds about 55 K in cash with (4.46 M) of positive cash flow from operations.
Check Arch Therapeutics Probability Of Bankruptcy
Ownership Allocation
Arch Therapeutics holds a total of 249.94 Million outstanding shares. Arch Therapeutics shows 14.58 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Arch Ownership Details

Arch Stock Price Odds Analysis

Coming from a normal probability distribution, the odds of Arch Therapeutics jumping above the current price in 90 days from now is about 82.07%. The Arch Therapeutics probability density function shows the probability of Arch Therapeutics otc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Arch Therapeutics has a beta of -2.055. This suggests as returns on its benchmark rise, returns on holding Arch Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Arch Therapeutics is expected to outperform its benchmark. Additionally, arch Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 1.96HorizonTargetOdds Above 1.96
17.89%90 days
 1.96 
82.07%
Based on a normal probability distribution, the odds of Arch Therapeutics to move above the current price in 90 days from now is about 82.07 (This Arch Therapeutics probability density function shows the probability of Arch OTC Stock to fall within a particular range of prices over 90 days) .

Arch Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Arch Therapeutics market risk premium is the additional return an investor will receive from holding Arch Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Arch Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Arch Therapeutics' alpha and beta are two of the key measurements used to evaluate Arch Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Arch Stock Against Markets

Picking the right benchmark for Arch Therapeutics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arch Therapeutics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arch Therapeutics is critical whether you are bullish or bearish towards Arch Therapeutics at a given time. Please also check how Arch Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Arch Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Arch Therapeutics Corporate Management

Elected by the shareholders, the Arch Therapeutics' board of directors comprises two types of representatives: Arch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Therapeutics' management team and ensure that shareholders' interests are well served. Arch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael AbramsChief OfficerProfile
Daniel YrigoyenVP SalesProfile
Terrence MDChairman, CoFounderProfile
Daniel WadsworthAdvisor CommercializationProfile

How to buy Arch OTC Stock?

Before investing in Arch Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Arch Therapeutics. To buy Arch Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Arch Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Arch Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Arch Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Arch Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Arch Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.

Already Invested in Arch Therapeutics?

The danger of trading Arch Therapeutics is mainly related to its market volatility and OTC Stock specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arch Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arch Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arch Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Therapeutics. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Arch OTC Stock analysis

When running Arch Therapeutics' price analysis, check to measure Arch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Therapeutics is operating at the current time. Most of Arch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Therapeutics' price. Additionally, you may evaluate how the addition of Arch Therapeutics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Equity Valuation
Check real value of public entities based on technical and fundamental data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Please note, there is a significant difference between Arch Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arch Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arch Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.